Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 633-644

  Mikulski, Stanislaw M ^a   Viera, Alejandro ^a   Deptala, Andrzej ^b   Darzynkiewicz, Zbigniew ^b  

^a Alfacell Corporation   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Cell cycle inhibition; Novel RNase; Pmteasome inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; N ACETYLLEUCINYLLEUCINYL METHIONINAL; N ACETYLLEUCINYLLEUCINYL NORLEUCINAL; N ACETYLLEUCINYLVALINYLPHENYL ALANINAL; PROTEINASE INHIBITOR; RANPIRNASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOPATHOGENIC EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN SYNTHESIS INHIBITION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 0031667074     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.633     Document Type: Article

References (62)

1. Schow SR and Joly A: N-acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-κB activation and prevents TNF and IL-6 synthesis in vivo. Cell Immunol 175: 199-202, 1997.
2. Drexler HCA: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94: 855-860, 1997.
3. Beg AA and Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274: 782-784, 1996.
4. Wang C-Y, Mayo MW and Baldwin AS: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274: 784-787, 1996.
5. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
6. Blank V, Kourilsky P and Israel A: NF-κB and related proteins: Rel/dorsal homologies meet ankyrin-like repeats. TIBS 17: 135-140, 1992.
7. Regnier CH, Yeong Song H, Gao X, Goeddel DV, Cao Z and Rothe M: Identification and characterization of an IκB kinase. Cell 90: 373-383, 1997.
8. Holtmann H, Hahn T and Wallach D: Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology 177: 7-22, 1988.
9. Kirstein M and Baglioni C: Tumor necrosis factor induces synthesis of two proteins in human fibroblasts. J Biol Chem 261: 9565-9567, 1986.
10. Wallach D: Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol 132: 2464-2469, 1984.
11. Wu Y-N, Mikulski SM, Ardelt W, Rybak SM and Youle RJ: A cytotoxic ribonuclease: study of the mechanism of onconase cytotoxicity. J Biol Chem 268: 10686-10693, 1993.
12. Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of pannon (P-30 protein), a novel anticancer asent. Cell Tissue Kinet 21: 169-182, 1988.
13. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, del Sal G, Chau V, Yew PR, Dractta GF and Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 631-632, 1995.
14. Hengst L and Reed SI: Translational control of p27Kip 1 accumulation during the cell cycle. Science 271: 1861-1864, 1996.
15. Mikulski SM: Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals (Review). Int J Oncol 4: 1257-1263, 1994.
16. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J and Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-548, 1997.
17. Mikulski SM, Viera A, Ardelt W, Menduke H and Shogen K: Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P-30 protein, a novel protein possessing anti-tumour activity. Cell Tissue Kinet 23: 237-246, 1990.
18. Berenbaum MC: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335, 1981.
19. Gorczyca W, Bruno S, Darzynkiewicz RJ, Gong J and Darzynkiewicz Z: DNA strand breaks occurring during apoptosis: their in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Oncol 1: 639-648, 1992.
20. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T and Traganos F: Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27: 1-20, 1997.
21. Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z: The cell cycle-related differences in susceptibility of HL-60 cells to apoptosis induced by various anti-tumor agents. Cancer Res 53: 3186-3192, 1993.
22. Li X and Darzynkiewicz Z: Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 28: 571-579, 1995.
23. Malinin NL, Boldin MP, Kovalenko AV and Wallach D: MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385: 540-544, 1997.
24. Yeong Song H, Regnier CH, Kirschning CJ, Goeddel DV and Rothe M: Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-κB and c-jun N terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 94: 9792-9796, 1997.
25. Maniatis T: Signal transduction: catalysis by a multiprotein IκB kinase complex. Science 278: 818-819, 1997.
26. Hsu H, Shu H-B, Pan M-G and Goeddel DV: TRADD-TRAF2 and TRADD- FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308, 1996.
27. Cao Z, Xiong J, Takeuchi M, Kurama T, and Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 383: 443-446, 1996.
28. Mercurio F, Zhu H, Murray BW, Shcvchenko A, Bennett BL, Wu LJ, Young DB, Barbosa M, Mann M, Manning A and Rao A: IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278: 860-866, 1997.
29. Woronicz JD, Gao X, Cao Z, Rothe M and Goeddel DV: IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 278: 866-869, 1997.
30. Chen Z, Hagler J, Palombclla VJ, Melandri F, Scherer D, Ballard D and Maniatis T: Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Dev 9: 1586-1597, 1995.
31. Lin Y-C, Brown K and Siebenlist U: Activation of NF-κB requires proteolysis of the inhibitor IκB-α: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc Natl Acad Sci USA 92: 552-556, 1995.
32. Kumar A, Haque J, Lacoste J, Hiscott J and Williams B: Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci USA 91: 6228-6292, 1994.
33. Maran A, Maitra R, Kumar A, Dong B, Xiao W, Li G, Williams B, Torrence P and Silverman R: Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 265: 789-792, 1994.
34. 2 and antioxidants have opposite effects on activation of NFkB and AP-1 in intact cells: AP-1 as secondary anti-oxidant-responsive factor. EMBO J 12: 2005-2015, 1993.
35. Traenckner EBM, Wilk S and Baeuerle PA: A proteasome inhibitor prevents activation of NFκB and stabilizes a newly phosphorylated form of IkBa that is still bound to NFκB. EMBO J 13: 5433-5441, 1994.
36. Brennan P and O'Neil L: Effects of oxidants and antioxidants on NF-κB activation in three different cell lines: evidence against a universal hypothesis involving oxygen radicals. Biochem Biophys Acta 1260: 1670-1675, 1995.
37. Suzuki Y, Mizuno M and Packer L: Transient overexpression of catalase does not inhibit TNF- or PMA-induced NF-κB activation. Biochem Biophys Res Commun 210: 537-541, 1995.
38. Koong A, Chen E and Giaccia A: Hypoxia causes the activation of NF-ê through the phosphorylation of IκBαon tyrosine residues. Cancer Res 54: 1425-1430, 1994.
39. Altuvia S, Weinstein-Fischer D, Zhang A, Postow L and Storz G: A small, stable RNA induced by oxidative stress: role as a pleiotropic regulator and antimutator. Cell 90: 43-53, 1997.
40. Wong GHW and Goeddel DV: Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242: 941-944, 1988.
41. Wong GHW, Elwell JH, Oberley LW and Goeddel DV: Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58: 923-931, 1989.
42. Deptala A, Halicka HD, Ardelt B, Ardelt W, Mikulski SM, Shogen K and Darzynkiewicz Z: Potentiation of tumor necrosis factor induced apoptosis by onconase. Int J Oncol 13: 11-16, 1998.
43. Mayo MW, Wang C-Y, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin AS: Requirement of NFκB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812-1815, 1997.
44. Lopes UG, Erhardt P, Yao R and Cooper GM: P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896, 1997.
45. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
46. Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-542, 1994.
47. Das KC and White CW: Activation of NF-κB by antincoplastic agents. J Biol Chem 272: 14914-14920, 1997.
48. Mansat V, Laurent G, Levade T, Bettaieb A and Jaffrezou J-P: The protein kinase C activators phorbol esters and phosphatidyl-serine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res 57: 5300-5304, 1997.
49. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Bcckett MA, Nodzenski E, Quintans J, Kufe DW and Weichselbaum RR: Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 57: 4340-4347, 1997.
50. Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung H-F and Longo DL: Enhancement of vincristine cytotoxicity in drugresistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst 88: 747-753, 1996.
51. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
52. Katayose Y, Kim M, Rakkar ANS, Li Z, Cowan KH and Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57: 5441-5445, 1997.
53. Kubbutat MH and Vousden KH: Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17: 460-468, 1997.
54. Tam SW, Theodoras AM and Pagano M: Kipl degradation via the ubiquitin-proteasome pathway. Leukemia 11 (Suppl 3): 363-366, 1997.
55. Boyer SN, Wazer DE and Band V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56: 4620-4624, 1996.
56. Hofmann F, Martelli F, Livingston DM and Wang Z: The retino-blastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 10: 2949-2959, 1996.
57. Baldin V, Cans C, Knibichlcr M and Ducommun B: Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its protcasome-dependent degradation. J Biol Chem 272: 32731-32734, 1997.
58. Brandeis M and Hunt T: The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBOJ 15: 5280-5289, 1996.
59. Chen Y, Sharp ZD and Lee WH: HEC binds to the seventh regulatory subunit of the 26S proteasome and modulates the proteolysis of mitotic cyclins. J Biol Chem 272: 24081-24087, 1997.
60. Ichihara A and Tanaka K: Roles of proteasomes in cell growth. Mol Biol Rep 21: 49-52, 1995.
61. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-234, 1997.
62. KIPI, and decreased pRb phosphorylation. Leukemia 12: 1241-1248, 1998.